JP2024537323A - 抗グリピカン３抗体 - Google Patents

抗グリピカン３抗体 Download PDF

Info

Publication number
JP2024537323A
JP2024537323A JP2024522070A JP2024522070A JP2024537323A JP 2024537323 A JP2024537323 A JP 2024537323A JP 2024522070 A JP2024522070 A JP 2024522070A JP 2024522070 A JP2024522070 A JP 2024522070A JP 2024537323 A JP2024537323 A JP 2024537323A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537323A5 (https=
Inventor
リウ ヤン，
ハオ シェン，
フェイフェイ ツイ，
レイ ファン，
Original Assignee
コンセプト トゥー メディシン バイオテック カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンセプト トゥー メディシン バイオテック カンパニー， リミテッド filed Critical コンセプト トゥー メディシン バイオテック カンパニー， リミテッド
Publication of JP2024537323A publication Critical patent/JP2024537323A/ja
Priority to JP2025006663A priority Critical patent/JP2025061426A/ja
Publication of JP2024537323A5 publication Critical patent/JP2024537323A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024522070A 2021-10-15 2022-10-17 抗グリピカン３抗体 Pending JP2024537323A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006663A JP2025061426A (ja) 2021-10-15 2025-01-17 抗グリピカン３抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/124182 2021-10-15
CN2021124182 2021-10-15
PCT/CN2022/125725 WO2023061505A1 (en) 2021-10-15 2022-10-17 Anti-glypican 3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006663A Division JP2025061426A (ja) 2021-10-15 2025-01-17 抗グリピカン３抗体

Publications (2)

Publication Number Publication Date
JP2024537323A true JP2024537323A (ja) 2024-10-10
JP2024537323A5 JP2024537323A5 (https=) 2025-11-10

Family

ID=85988149

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024522070A Pending JP2024537323A (ja) 2021-10-15 2022-10-17 抗グリピカン３抗体
JP2025006663A Pending JP2025061426A (ja) 2021-10-15 2025-01-17 抗グリピカン３抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006663A Pending JP2025061426A (ja) 2021-10-15 2025-01-17 抗グリピカン３抗体

Country Status (5)

Country Link
US (2) US20240409663A1 (https=)
EP (2) EP4416187A1 (https=)
JP (2) JP2024537323A (https=)
CN (3) CN118488970A (https=)
WO (1) WO2023061505A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4591887A1 (en) * 2022-09-22 2025-07-30 Lepu Biopharma Co., Ltd. Gpc3 antibody-drug conjugate and use thereof
WO2024067764A1 (zh) * 2022-09-30 2024-04-04 信立泰(成都)生物技术有限公司 抗gpc3单克隆抗体/双特异性抗体或其抗原结合片段及其用途
WO2025045242A1 (zh) * 2023-09-01 2025-03-06 信立泰(成都)生物技术有限公司 一种靶向gpc3的双特异性抗体或抗原结合片段及其用途
TW202525864A (zh) * 2023-09-05 2025-07-01 大陸商上海美雅珂生物技術有限責任公司 靶向ｇｐｃ３的抗體藥物偶聯物及其應用
WO2025159562A1 (ko) * 2024-01-24 2025-07-31 국립암센터 Gpc3에 특이적으로 결합하는 신규 항체 및 이의 용도
WO2026016998A1 (zh) * 2024-07-15 2026-01-22 北京剂泰医药科技有限公司 编码针对GPC3和CD3双特异性抗体的mRNA分子

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
KR100953520B1 (ko) * 2001-06-22 2010-04-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 항암제
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
ME02345B (me) * 2007-07-17 2016-08-31 Squibb & Sons Llc MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
CN101633693A (zh) * 2009-08-24 2010-01-27 中国人民解放军第二军医大学 一种抗gpc3的单克隆抗体
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
US9926377B2 (en) * 2014-05-22 2018-03-27 Genentech, Inc. Anti-GPC3 antibodies and immunoconjugates
CN105037540A (zh) * 2015-05-13 2015-11-11 北京比洋生物技术有限公司 抗磷脂酰肌醇蛋白聚糖3全人源抗体
ES2883240T3 (es) * 2015-08-03 2021-12-07 Cafa Therapeutics Ltd Anticuerpo contra glipicano-3 y aplicación del mismo
US11767362B1 (en) * 2016-03-15 2023-09-26 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
EP3615574A4 (en) * 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
CN109988240B (zh) * 2017-12-29 2022-06-28 安源医药科技（上海）有限公司 抗gpc-3抗体及其用途
CN109021108B (zh) * 2018-08-27 2019-06-25 南京医科大学 抗gpc3全人源化抗体、其嵌合抗原受体细胞及应用
KR20220083665A (ko) * 2019-08-01 2022-06-20 알.피.쉐러 테크놀러지즈 엘엘씨 Gpc3에 특이적인 항체 및 그것의 사용 방법

Also Published As

Publication number Publication date
US20240409663A1 (en) 2024-12-12
EP4416187A1 (en) 2024-08-21
CN118994403B (zh) 2025-04-01
EP4527465A3 (en) 2025-07-09
US20250154280A1 (en) 2025-05-15
WO2023061505A1 (en) 2023-04-20
JP2025061426A (ja) 2025-04-10
EP4527465A2 (en) 2025-03-26
CN118994403A (zh) 2024-11-22
CN119080937A (zh) 2024-12-06
CN118488970A (zh) 2024-08-13

Similar Documents

Publication Publication Date Title
CN118994403B (zh) 抗磷脂酰肌醇蛋白聚糖3抗体
KR102649942B1 (ko) 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트
KR20210125511A (ko) 항-cd228 항체 및 항체-약물 컨쥬게이트
US20250011427A1 (en) Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
US20250186601A1 (en) Antibodies targeting liv-1 and uses thereof
AU2026200978A1 (en) Anti-5T4 antibodies and uses thereof
WO2025011462A1 (en) Single domain antibodies for gprc5d
US20250313632A1 (en) Anti-b7-h3 antibodies and uses thereof
US12180276B2 (en) Antibodies and antibody-drug conjugates targeting claudin 6
HK40113267A (zh) 抗磷脂酰肌醇蛋白聚糖3抗体
HK40117975A (zh) 抗b7-h3抗体及其用途
HK40117975B (zh) 抗b7-h3抗体及其用途
HK40112932A (zh) 抗5t4抗体及其用途
WO2025260010A2 (en) Anti-nectin-4 antibodies and uses of the same
TW202342529A (zh) 抗il-13ra2單株抗體及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251119